Early trial halted for new myeloma drug combo
NCT ID NCT05590377
Summary
This early-stage study tested the safety and initial effectiveness of a new drug, modakafusp alfa, when given alongside an existing drug, daratumumab, for people with multiple myeloma that has returned or stopped responding to other treatments. The main goal was to find a safe dose and see how the body processes the new drug. The study was terminated early by the sponsor for strategic reasons before the main effectiveness phase could begin.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
CHRU Lille
Lille, Hauts-de-France, 59037, France
-
Cedars-Sinai Medical Center
Los Angeles, California, 77598, United States
-
Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont
Sherbrooke, Quebec, J1H 5N4, Canada
-
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, 58128, South Korea
-
Concord Repatriation General Hospital
Concord, New South Wales, 2139, Australia
-
Floating Hospital for Children at Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana, 46060, United States
-
Fundacion Instituto de Estudios Ciencias de la Salud de Castilla y Leon-Investigacion Biomedica de Salamanca (IBSAL)
Salamanca, 37007, Spain
-
HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division)
Overland Park, Kansas, 66211, United States
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Institut Paoli-Calmettes
Marseille, Provence-Alpes-Côte d'Azur Region, 13273, France
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, 300020, China
-
New York Cancer and Blood Specialists
Bay Shore, New York, 11706, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Stony Brook University Hospital
Stony Brook, New York, 11794, United States
-
Summit Medical Group PA
Florham Park, New Jersey, 07932, United States
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
The Catholic University of Korea, Seoul St. Marys Hospital
Seoul, 06591, South Korea
-
Tranquil Clinical Research
Webster, Texas, 78041, United States
-
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
University of Cincinnati - Vontz Center for Molecular Studies
Cincinnati, Ohio, 45267, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Washington University School of Medicine
St Louis, Missouri, 63130, United States
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
-
Zhejiang University School of Medicine - The First Affiliated Hospital (Zhejiang Provincial First Hospital)
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.